Hong Kong Healthtech Stock News

Shenzhen International Holdings (SEHK:152) has just been added to the Hang Seng China Affiliated Corporations Index, putting the HK$9.16 stock on the radar of index-tracking funds and investors who monitor benchmark-linked flows. See our latest analysis for Shenzhen International Holdings. The index add comes after a period where momentum has been building, with Shenzhen International Holdings posting a 10.49% 90 day share price return and a 31.43% 1 year total shareholder return. This points...

Lee & Man Paper Manufacturing (SEHK:2314) opened FY 2025 with first half revenue of HK$12.2b and basic EPS of HK$0.19, setting the tone after a year in which trailing twelve month EPS reached HK$0.45. The company has seen revenue move from HK$12.5b in the first half of FY 2024 to HK$13.5b in the second half and then to HK$12.2b in the latest period, while net income shifted from HK$760.2m to HK$552.6m and now HK$811.1m. This frames the current results against a year of recovering margins and...

Xiaomi (SEHK:1810) has stayed in focus for Hong Kong tech investors, with the stock showing mixed returns over the past week, month and past 3 months as sentiment around Chinese equities remains cautious. See our latest analysis for Xiaomi. At around HK$33.34, Xiaomi’s recent share price has been volatile, with a 7 day share price return of 4.19% sitting against a 30 day share price return decline of 5.28% and a year to date share price return decline of 17.23%. The 1 year total shareholder...

Horizon Robotics Index Inclusion Triggers Fresh Investor Focus Horizon Robotics (SEHK:9660) has been added to the Hang Seng China Enterprises Index, a move that can draw fresh attention as index tracking funds and benchmark aware investors review their allocations. See our latest analysis for Horizon Robotics. The latest index inclusion comes after a mixed run for the shares, with a 1-day share price return of 1.31%, a year-to-date share price decline of 14.24%, and a 1-year total shareholder...

XD Inc. (SEHK:2400) issued unaudited earnings guidance for 2025, projecting revenue of at least CN¥5,710 million and net profit of at least CN¥1,580 million, both higher than its 2024 reported figures. See our latest analysis for XD. XD's HK$74.8 share price has seen a 20.35% 90 day share price return and a 96.11% 1 year total shareholder return, suggesting momentum has strengthened ahead of the 2025 guidance, while shorter term moves remain choppy. If this guidance has you thinking about...

Horizon Construction Development (SEHK:9930) has reported its FY 2025 first half results with revenue of C¥4.4b and basic EPS of C¥0.011, while prior periods show revenue of C¥4.9b and EPS of C¥0.084 in 2024 H1 and revenue of C¥6.7b with EPS of C¥0.199 in 2024 H2. Over the trailing twelve months, revenue has ranged from C¥9.4b to C¥11.6b with EPS between C¥0.05 and C¥0.282. This sets up a picture where expectations for growth potential now have to be weighed against pressure on margins and...

Natural Beauty Bio-Technology (SEHK:157) has posted its FY 2025 first half results with revenue of HK$264.5 million and basic EPS of HK$0.005459, setting a very different tone from the losses recorded through FY 2024. The company has seen revenue move from HK$156.7 million in 1H 2024 to HK$196.9 million in 2H 2024 and then to HK$264.5 million in 1H 2025, while EPS shifted from losses of HK$0.015211 and HK$0.036542 in the two halves of 2024 to a small profit in the latest period, supported by...

Impro Precision Industries (SEHK:1286) has reported FY 2025 first half revenue of HK$2,449.9 million and basic EPS of HK$0.18, with trailing twelve month revenue at HK$5.1 billion and EPS at HK$0.39 framing the latest numbers in a broader context. Over the last three reported half year periods, revenue has moved from HK$2,402.5 million in 1H 2024 to HK$2,284.3 million in 2H 2024 and then to HK$2,449.9 million in 1H 2025, while basic EPS has shifted from HK$0.16 to HK$0.18 over the same span,...

Chinese Estates Holdings (SEHK:127) has reported FY 2025 first half revenue of HK$42.7 million, with basic EPS at a loss of HK$0.215 per share as the group continues to work through a weak earnings patch. The company has seen revenue move from HK$183.9 million in the first half of 2024 to HK$41.8 million in the second half of 2024 and HK$42.7 million in the latest period. Basic EPS losses shifted from HK$0.221 to HK$0.884 and then HK$0.215, setting up an earnings season where investors may...

Lee & Man Chemical (SEHK:746) has released its FY 2025 first half numbers, reporting revenue of HK$1,931.9 million and basic EPS of HK$0.40, with investors weighing these results against a trailing twelve month EPS of HK$0.68. The company has seen half year revenue shift from HK$1,989.7 million in 1H 2024 and HK$1,961.1 million in 2H 2024 to HK$1,931.9 million in 1H 2025. EPS moved from HK$0.29 in each half of FY 2024 to HK$0.40 in the latest period, highlighting a narrative that now focuses...

Wharf Real Estate Investment (SEHK:1997) has posted softer full year numbers for FY 2025, with second half revenue at HK$6.4b and basic EPS of a HK$0.61 loss, against HK$6.4b of revenue and basic EPS of HK$0.64 in the second half of FY 2024. Over the trailing twelve months to the second half of FY 2025, the company has seen revenue sit at about HK$12.8b while basic EPS moved from HK$0.29 to a HK$1.40 loss. This underscores the pressure on reported earnings even as the top line holds broadly...

Jacobio Pharmaceuticals Group (SEHK:1167) opened FY 2025 with first half revenue of C¥45.7 million and a basic EPS loss of C¥0.08, while trailing 12 month figures show revenue of C¥53.5 million and a basic EPS loss of about C¥0.19, underlining that the business is still in loss making territory on a full year view. The company has seen revenue move from C¥155.7 million with basic EPS of C¥0.02 in 2H 2024 to C¥45.7 million with basic EPS of C¥0.08 loss in 1H 2025, against a trailing 12 month...

Latest FY 2025 Earnings Snapshot Fortune Real Estate Investment Trust (SEHK:778) has posted its FY 2025 first half numbers with revenue of HK$854.5 million and basic EPS of HK$0.32 loss per share, setting a cautious tone for the latest results. Over the recent reporting periods, revenue has moved from HK$871.8 million in 1H 2024 to HK$874.5 million in 2H 2024 and now HK$854.5 million in 1H 2025. Over the same intervals, basic EPS shifted from a HK$0.02 loss to a HK$0.24 loss and then a...

IMAX China Holding FY 2025 Earnings Snapshot IMAX China Holding (SEHK:1970) has wrapped up FY 2025 with second half revenue of US$44.5 million and basic EPS of US$0.04, alongside trailing 12 month EPS of US$0.11 on revenue of US$102.3 million that reflects a 69.6% earnings increase over the past year. The company has seen revenue move from US$37.1 million and EPS of US$0.03 in the second half of 2024 to US$44.5 million and EPS of US$0.04 in the second half of 2025, while trailing net income...

In March 2026, BYD Company Limited reported that its February production and sales volumes were lower than a year earlier, while also unveiling its FLASH Charging technology and second-generation Blade Battery with faster charging and improved energy density. These battery and charging innovations, including very high-power FLASH Charging and an expanded station rollout plan, signal BYD’s push to reshape how quickly and efficiently electric vehicles can be recharged in China and...

ASMPT (SEHK:522) has packed several updates into its latest announcement, combining first quarter 2026 revenue guidance, higher proposed dividends, and the planned divestment of NEXX into a single reference point for investors. See our latest analysis for ASMPT. Those updates are landing after a strong run in the shares, with ASMPT’s 90 day share price return of 45.27% and 1 year total shareholder return of 94.12% pointing to momentum building as investors reassess growth prospects and...

Guidance-driven spotlight on Simcere Pharmaceutical Group Simcere Pharmaceutical Group (SEHK:2096) has issued consolidated guidance for 2025, indicating expected revenue of RMB 7,700 million to RMB 7,800 million and profit attributable to equity shareholders of RMB 1,300 million to RMB 1,400 million. See our latest analysis for Simcere Pharmaceutical Group. The guidance update comes after a mixed share price run, with a 7 day share price return of 3.55% and a 90 day share price return decline...

Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding coverage across all treatment lines. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$1.49, the stock has seen a 6.43% 7 day share price return and a 16.41% 90 day share price return. The 1 year total shareholder return of 150.06% points to strong momentum,...

CLP Holdings (SEHK:2) is back in focus after releasing its full year 2025 results. The company reported lower sales and net income year on year and declared a fourth interim dividend of HK$1.31 per share. See our latest analysis for CLP Holdings. At a share price of HK$74.75, CLP Holdings has delivered a 10.82% 90 day share price return and a 21.83% 1 year total shareholder return, suggesting momentum has been rebuilding recently despite softer reported earnings. If this earnings and dividend...

Laopu Gold (SEHK:6181) has been added to the Hang Seng Index, an event that can increase attention from index funds and benchmarked investors as they reassess exposure to Hong Kong listed jewelry names. See our latest analysis for Laopu Gold. The index inclusion comes after a period where Laopu Gold’s 90 day share price return of 2.65% and year to date share price return of 2.73% contrast with a 1 year total shareholder return decline of 5.48%, suggesting short term momentum has picked up...

Longfor Group Holdings (SEHK:960) has drawn fresh attention after issuing unaudited 2025 earnings guidance that indicates a sharp drop in profit and a core net loss, despite continued positive operating cash flow. See our latest analysis for Longfor Group Holdings. The earnings guidance and recent sales update come after a choppy period for the share price, with a 1-month share price return showing a 10.81% decline and a 1-year total shareholder return showing a 14.61% decline, pointing to...

In early March 2026, Air China announced the retirement of Vice Chairman and President Wang Mingyuan and appointed airline veteran Qu Guangji as the new President, alongside a reshuffle of key board committees. The concentration of responsibilities across Air China’s Strategy, Audit, Nomination, Remuneration, and Aviation Safety committees highlights how governance structures may shape management decisions under the new leadership. Next, we examine how this leadership transition,...

If you are wondering whether China Development Bank Financial Leasing is still sensibly priced, or if the recent share price puts it in bargain territory, you are in the right place. The stock most recently closed at HK$1.48, with returns of 30.9% over 1 year, 69.3% over 3 years and 90.7% over 5 years, even though the share price has seen a 3.9% decline over 7 days, 6.3% over 30 days and 16.4% year to date. Recent coverage has focused on the company as a Hong Kong listed leasing arm of a...

Recent performance snapshot for HBM Holdings HBM Holdings (SEHK:2142) has been on the radar after recent price moves, with the stock showing a mix of gains over the past month and past 3 months alongside longer term total return figures. See our latest analysis for HBM Holdings. The recent 1 day share price return of 6.34% and 7 day return of 7.37% at a HK$12.24 share price sit against a 30 day share price return of 10.97%, a 90 day share price decline of 11.50% and a very large 3 year total...